Amawakawaka ezigulana aqala kwi-Saxenda yemihla ngemihla ngoku abuza umbuzo ofanayo: ngaba lixesha lokufudukela kwi-Wegovy kanye ngeveki, kwaye utshintsho kufuneka lwenziwe njani ngokukhuselekileyo? Omabini amayeza ayi-GLP-1 receptor agonists eyenziwe nguNovo Nordisk, kodwa asebenzisa iimolekyuli ezahlukeneyo (liraglutide vs semaglutide), izingqisho zedosi ezahlukeneyo kunye neeshedyuli ezahlukeneyo ze-titration. Ukufumana inguqu ngokufanelekileyo kukhusela ukunyamezeleka, kugcina amandla okwehla kobunzima kwaye kunqanda iimpazamo eziqhelekileyo ezinjengokutyhoboza la machiza mabini.
Ukuba ufuna ukujonga intloko-to-intloko ukuba leliphi ichiza elifanele isigulana, bona isikhokelo sethu sangaphambili, Ukuthelekisa i-Wegovy kunye ne-Saxenda: Yiyiphi i-Weight Loss Medicine ekulungele wena . Eli nqaku ligxininise kwinto eyahlukileyo: inkqubo ebonakalayo yokutshintsha ukusuka kwi-Saxenda ukuya kwi-Wegovy, ukugubungela ixesha, ukuqala kwedosi, i-titration kunye neziphi izigulane kunye neekliniki kufuneka zilindele kwiinyanga zokuqala.
Kutheni izigulana zitshintsha ukusuka eSaxenda ukuya kwiWegovy
Ezona zizathu zixhaphakileyo oogqirha bajonga inguqu ye-Saxenda ukuya kwi-Wegovy zezi:
Ukwehla kobunzima obukhulu kumndilili. Kwi-STEP 8 isilingo esingenasiphelo, abantu abadala abangenaso isifo sikashukela balahlekelwa yi-15.8% yesisindo somzimba kwi-semaglutide 2.4 mg ngeveki kunye ne-6.4% kwi-liraglutide 3.0 mg imihla ngemihla kwiiveki ze-68 (Rubino et al., JAMA 2022).
Izitofu ezimbalwa. Inaliti enye ngeveki endaweni yesixhenxe yenza ubambelelo lube lula kubantu abaninzi.
Ithafa eSaxenda. Ileyibhile ye-Saxenda icebisa ukuyeka unyango ukuba umntu omdala akazange alahlekelwe ubuncinane be-4% yesisindo esisisiseko emva kweeveki ze-16, nto leyo eyenza ukuba abaninzi abamiselweyo bahlolisise ezinye iindlela.
Unikezelo, iindleko okanye utshintsho lwe-inshurensi , eyahlukileyo ngokwelizwe kwaye itshintsha rhoqo.
Ukutshintsha akunyanzelekanga. Isikhokelo soguqulo seMicimbi yamaVetera e-US akukho mfuneko yokuguqula isigulana esiqhuba kakuhle kwaye sinciphise ubunzima kwi-liraglutide. Isigqibo kufuneka sihlale singumntu.
Saxenda vs Wegovy Dosing ngokuJonga nje
Ngokwengxelo esemthethweni yase-US yolwazi:
I-Saxenda (liraglutide) itofwa ngaphantsi kwesikhumba kanye yonke imihla . Iqala kwi-0.6 mg ngosuku kwiveki enye kwaye iphakama nge-0.6 mg ngeveki (1.2 mg, 1.8 mg, 2.4 mg) kude kube yi-3 mg idosi yokugcinwa kwemihla ngemihla ifikeleleke kwiveki ye-5. Amanani aphantsi aphantsi kwe-titration kuphela.
Inaliti ye-Wegovy (semaglutide) inikezelwa ngaphantsi kwe-subcutaneously kanye ngeveki , ngosuku olufanayo ngeveki nganye. Ishedyuli yokunyuka yile:
Ileyibhile yangoku yase-US iphinde ivumele abantu abadala abaye banyamezela i-2.4 mg ubuncinane kwiiveki ze-4 ukuba banyuke ukuya kubuninzi be-7.2 mg ngeveki xa ukunciphisa ubunzima obungaphezulu kuboniswa ngekliniki. Amanani kunye namandla akhoyo ayahluka ngokwamazwe, ngoko hlala ulandela ileyibhile yendawo. Ukufumana imvelaphi malunga nendlela i-semaglutide esebenza ngayo, funda Ukuqonda i-Semaglutide Injection kunye nokusetyenziswa kwayo.
Zombini iilebhile zithi ichiza akufuneki lidityaniswe nayo nayiphi na enye iGLP-1 receptor agonist. Loo mgaqo omnye ubumba yonke inkqubo yokutshintsha.
Ukutshintsha njani ukusuka eSaxenda ukuya kwi-Wegovy: Inyathelo ngenyathelo
Ayikho i-Wegovy okanye ileyibhile ye-Saxenda equlethe i-protocol esemthethweni yokutshintsha i-Saxenda-to-Wegovy. Oku kulandelayo kubonisa ukupapashwa kwesikhokelo seklinikhi kunye nokusebenza okuqhelekileyo. Umyaleli uhlala esenza umnxeba wokugqibela.
Inyathelo 1: Hlaziya iSizathu soTshintsho
Oogqirha baqinisekisa kuqala ukuba kutheni isigulane sifuna ukutshintsha, nokuba ngaba oko kusebenza, kulula, iindleko okanye iziphumo ebezingalindelekanga. Emva koko bajonga kwakhona contraindications. I-Wegovy akufanele isetyenziswe kwizigulane ezinembali yomntu okanye yentsapho ye-medullary thyroid carcinoma okanye i-MEN 2, kwaye abantu abanesifo seswekile se-2 bafuna ukuhlolwa kwe-glucose ngexesha lokutshintsha.
Inyathelo lesi-2: Ixesha-Akufuneki Ukuhlamba
Isikhokelo esisebenzayo esipapashwe kwi- Clinical Diabetes (Almandoz, Lingvay kunye neMorales, 2020) icebisa ukuba isigulana esinyamezela i-agonist ye-GLP-1 yemihla ngemihla ngedosi epheleleyo inokuqalisa iarhente yeveki ngosuku emva kwedosi yokugqibela yemihla ngemihla . Inkonzo yeNgcaciso yeChristchurch Medicines yaseNew Zealand (2025) ngokunjalo ithi akukho xesha lokuhlamba lifunekayo. Ukuthatha omabini amachiza kunye akukhuthazwa phantsi kwayo nayiphi na ileyibhile.
Kukho enye ngaphandle. Ukuba utshintsho lwenzeka ngenxa yeziphumo ebezingalindelekanga zesisu, isikhokelo esifanayo sicebisa ukumisa i-Saxenda kwaye ulinde de iimpawu zisombulule ngaphambi kokuba uqale i-Wegovy ngedosi yayo ephantsi.
Inyathelo 3: Khetha iDose yokuQalisa
I-Liraglutide 3 mg yonke imihla kunye needosi ze-semaglutide azitshintshi ngokuthe ngqo, kwaye akukho kulinganisa okuqinisekisiweyo. Iitheyibhile zoguqulo ezipapashiweyo zithatha indlela yogcino:
Izigulana kwi-Saxenda 0.6–1.2 mg yonke imihla: ngokuqhelekileyo iqala i-Wegovy kwi- 0.25 mg ngeveki.
Izigulane kwi-1.8-2.4 mg imihla ngemihla: 0.25 mg okanye i-0.5 mg ngeveki.
Izigulane zizinzile kwi-3 mg imihla ngemihla: ezinye iinkonzo (VA, CMIS) zicebisa i-0.5 mg ngeveki njengendawo yokuqala yokuqalisa.
Ukuqala kwi-0.25 mg, njengoko ileyibhile ye-Wegovy incoma, ihlala ilumkile kwaye ilungelelaniswe neleyibhile.
Inyathelo lesi-4: Yandisa rhoqo kwiiveki ezi-4
Ukususela kwi-dose yokuqala, i-Wegovy inyuswa rhoqo kwiiveki ezi-4 ukuya kwi-1.7 mg okanye i-2.4 mg. Ukuba idosi ayinyanzelwanga kakuhle, ileyibhile ivumela ukunyuka okulandelayo ukubambezeleka ngeeveki ezi-4. Kwiidosi eziphosiweyo, ileyibhile ithi ukuba idosi enye ilahlekile kwaye elandelayo ingaphezulu kweentsuku ezi-2, kufuneka ithathwe ngokukhawuleza. Ukuba iidosi ezimbini okanye ngaphezulu ezilandelelanayo zilahlekile, ukunyuka kwakhona ukusuka kwidosi ephantsi kunokufuneka.
Yintoni omele uyilindele emva koTshintsho
Iimpembelelo zeGastrointestinal
Isicaphucaphu, urhudo, ukugabha kunye nokuqhinwa zezona ziphumo zibi zixhaphakileyo kuwo omabini amayeza. Kwi-STEP 8, iziganeko zesisu zichazwe yi-84.1% yabasebenzisi be-semaglutide kunye ne-82.7% yabasebenzisi be-liraglutide, ubukhulu becala buncinci ukuya kumodareyitha. Nangona kunjalo, abathathi-nxaxheba abambalwa bayeka i-semaglutide (13.5%) kune-liraglutide (27.6%). Ukutya okuncinci, ukuyeka ukutya xa ugcwele kwaye uhlala u-hydrated kunceda uninzi lwezigulane ngenyathelo ngalinye elitsha ledosi.
Ubunzima-Ilahleko Trajectory
Ngenxa yokuba idosi ye-Wegovy yokuqala iphantsi, ezinye izigulane ziqaphela ukubuya okuncinci kokutya kwiiveki zokuqala emva kokuyeka i-3 mg ye-Saxenda. Oku kudla ngokuhlala njengoko ithamo linyuka. Kwi-STEP 8, i-70.9% yabathathi-nxaxheba kwi-semaglutide iphumelele ubuncinane i-10% yokulahlekelwa kwesisindo, xa kuthelekiswa ne-25.6% kwi-liraglutide. Iziphumo zisaxhomekeke kwisidlo, umsebenzi kunye nebhayoloji yomntu.
Utshintsho ebusweni kunye nomzimba
Ngokukhawuleza, ukulahlekelwa kwesisindo esinzulu kunokubonakalisa ukulahleka kwevolumu kwiitempile, izihlathi kunye nomhlathi, okubizwa ngokuba 'ubuso be-Ozempic'. Iiklinikhi zobuhle ziya zihambelanisa izigulane zolawulo lobunzima kunye nonyango lokubuyisela. Inqaku lethu Ngaba iiFili zeDeermal zingabubuyisela umva uBuso be-Ozempic? Oonobangela kunye noKhetho loNyango luchaza iindlela onokukhetha kuzo.
Iimpazamo eziqhelekileyo xa uTshintsho kwi-Saxenda ukuya kwi-Wegovy
Ukugqithisa amachiza amabini. Musa ukuthatha idosi yokugqibela ye-Saxenda kwangolo suku olunye nenaliti ye-Wegovy yokuqala.
Ukutsiba ngqo kwi-2.4 mg. Ukweqa i-titration kuphakamisa umngcipheko wokuphendula okubukhali kwe-GI kunye nokulimala kwezintso ezinxulumene nokuphelelwa ngamanzi emzimbeni.
Ukunyanga iidosi ngokulinganayo. I-3 mg ye-liraglutide 'ayifani' nayo nayiphi na idosi ye-semaglutide.
Ukungawahoyi amayeza eswekile. Izigulana ezisebenzisa i-insulin okanye i-sulfonylureas zinokufuna uhlengahlengiso lwethamo ukunqanda i-hypoglycaemia.
Ukusebenzisa iimveliso 'semaglutide' ezingalawulwayo. Izigulane kufuneka zisebenzise kuphela iimveliso ezigunyazisiweyo, ezimiselweyo kwii-pharmacy ezisemthethweni.
Kuthetha ukuthini Oku kwiiklinikhi kunye naBasasazi
Kwiikliniki zobuhle kunye nempilo entle, ukunyuka konyango lweveki ye-GLP-1 kuhlengahlengisa uhambo lwezigulane. Izigulana ezikulawulo lobunzima bonyango zihlala zifuna unyango lokujonga umzimba, umgangatho wolusu kunye nokubuyisela umthamo ngexesha okanye emva kwenkqubo yazo. Isishwankathelo sethu se I-Ton-Non-Surgicing Body Contouring kunye ne-Weight Management Trends kwiimephu ze-2026 apho imfuno ihamba khona.
Iibhrendi kunye nabasasazi abakha ipotfoliyo yolawulo lobunzima kufuneka badibanise ukhathalelo lwe-GLP-1 kagqirha kuphela, oluhlala phantsi kweliso likagqirha, kunye neemveliso ezongezelelweyo ezithobelayo ezifana nezihluzi, izivuseleli zecollagen, i-mesotherapy kunye nezitofu ezijikeleza umzimba. Ukuqonda indlela intsebenziswano yeleyibhile yabucala esebenza ngayo, funda Ukuphonononga i-OEM yokuLahla ubunzima: Ithuba eliCwangcisiweyo leMpilo kunye neMpilo yamaShishini . I-AOMA ixhasa amaqabane kunye ne-GMP-based production, amaxwebhu alawulayo kunye nophawu lwesiko.
FAQ
Ngaba ndingaqalisa i-Wegovy kusuku olusemva kwesitofu sam sokugqibela seSaxenda?
Kwiimeko ezininzi, ewe. Isikhokelo esipapashiweyo sichaza ukuba akukho kuhlamba kufunekayo, kwaye i-arhente yeveki inokuqalisa ngosuku emva kwedosi yokugqibela yemihla ngemihla. Ukuba uyatshintsha ngenxa yeziphumo ebezingalindelekanga, ugqirha wakho unokukucela ukuba ulinde de ziphele iimpawu.
Yeyiphi idosi ye-Wegovy ekufuneka ndiqale ngayo emva kwe-Saxenda 3 mg?
Ileyibhile ye-Wegovy iqala wonke umntu kwi-0.25 mg ngeveki. Ezinye iinkonzo zeklinikhi zithatha i-0.5 mg ngaphandle kweleyibhile kwizigulane ezizinzileyo kwi-Saxenda 3 mg. I-prescriber yakho yenza isigqibo ngokusekelwe kunyamezelo lwakho.
Ndingathatha i-Saxenda kunye ne-Wegovy kunye?
Hayi. Zombini iilebhile zichaza ukuba ukudibanisa kunye nayo nayiphi na enye i-agonist ye-GLP-1 ye-receptor ayikhuthazwa.
Kuthatha ixesha elingakanani ukufikelela kwidosi ye-Wegovy epheleleyo?
Ukususela kwi-0.25 mg, ukufikelela kwi-2.4 mg kuthatha iiveki ze-16, kunye nokugcinwa kweveki ye-17. Ukuqala kwi-0.5 mg kunciphisa oku malunga neeveki ze-4.
Ngaba i-Wegovy isebenza ngakumbi kuneSaxenda?
Kwi-STEP 8 intloko-to-head trial, i-semaglutide i-2.4 mg ivelise i-avareji ye-15.8% yokulahleka kwesisindo ngokuchasene ne-6.4% kunye ne-liraglutide 3.0 mg kwiiveki ze-68. Iziphumo zomntu ngamnye ziyahluka.
Medical Disclaimer
Eli nqaku lenzelwe iinjongo zemfundo jikelele kunye nezempilo kunye neengcali zoshishino. Ayiyongcebiso yezonyango. I-Saxenda kunye ne-Wegovy ngamayeza amiselweyo kuphela. Naluphi na utshintsho kunyango, kubandakanywa nexesha kunye ne-dosing, kufuneka ligqitywe ngumyalelo ogunyazisiweyo ngokweenkcukacha ezimiselweyo zendawo. I-AOMA ayenzi okanye ithengise i-Saxenda okanye i-Wegovy, eziziimpawu zorhwebo zeNovo Nordisk A/S.
Iimbekiselo
Rubino DM, Greenway FL, Khalid U, et al. Impembelelo yeveki engaphantsi kwe-semaglutide vs i-liraglutide yemihla ngemihla kubunzima bomzimba kubantu abadala abatyebileyo okanye abatyebe kakhulu ngaphandle kweswekile: ISINYATHELO 8 solingo lwekliniki olungacwangciswanga. JAMA . 2022;327(2):138-150. PMID: 35015037.
Almandoz JP, Lingvay I, Morales J, et al. Ukutshintsha phakathi kwe-glucagon-like peptide-1 receptor agonists: ingqiqo kunye nesikhokelo esisebenzayo. UClin isifo seswekile . 2020;38(4):390-402. PMID: 33132510.
I-WEGOVY (semaglutide) i-injection / tablets, i-US Prescribing Information, i-Novo Nordisk (i-DailyMed, ihlaziywe ngoJuni 2026).
Isitofu se-SAXENDA (liraglutide), i-US yokuchaza iNkcukacha, iNovo Nordisk (iDailyMed / FDA, 2026).
Isebe leMicimbi yamagqala aseMelika. I-Semaglutide (WEGOVY) isikhokelo sokuguqulwa kwesitofu esingaphantsi kwesikhumba solawulo lobunzima, ngoFebruwari 2023.
Christchurch Medicines Information Service. Ukutshintshela kwi-liraglutide (Saxenda) ukuya kwi-semaglutide (Wegovy), ngoJulayi 2025.
